First Cycle Approval Rate Tops 50% For 2006 NMEs; Merck Hits 100%
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Merck skillfully navigated FDA’s approval process in 2006, receiving all five of its new molecular entity and novel biologic approvals after only a single review cycle.